Clemmer James C

SEC source: 0001140361-26-029633 · form4.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 184,361 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 19, 2023, the reporting person received a target grant of 184,361 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 52,358 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 19, 2023, the reporting person received a target grant of 184,361 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 52,358 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 19, 2023, the reporting person received a target grant of 184,361 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 52,358 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-26-029633 · form4.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 862,448

F2 · shares: The exempt disposition of 26,728 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029633 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 889,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 52,358 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029178 · form4.xml · nonDerivative · entry 5

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 836,818

F5 · shares: The exempt disposition of 4,223 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-26-029178 · form4.xml · nonDerivative · entry 4

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 841,041

F4 · shares: The exempt disposition of 487 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2024.

SEC source: 0001140361-26-029178 · form4.xml · nonDerivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 841,528

F3 · shares: The exempt disposition of 11,764 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029178 · form4.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 853,292

F2 · shares: The exempt disposition of 10,649 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2024.

SEC source: 0001140361-26-029178 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 863,941

F1 · shares: The exempt disposition of 18,588 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 16, 2025.

SEC source: 0001140361-25-037836 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 882,529

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.10 to $11.17 inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

SEC source: 0001140361-25-026797 · form4.xml · nonDerivative · entry 4

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 872,529

F4 · shares: The exempt disposition of 3,673 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-25-026797 · form4.xml · nonDerivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 876,202

F3 · shares: The exempt disposition of 2,982 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-25-026797 · form4.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 879,184

F2 · shares: The exempt disposition of 8,307 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-25-026797 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 887,491

F1 · shares: The exempt disposition of 344 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2024.

SEC source: 0001140361-25-026464 · form4.xml · derivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206,253

Underlying: Common Stock · 206,253 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-25-026464 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 887,835

F1 · shares: The acquisition of 206,253 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 206,253 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 16, 2026, such that 25% of the restricted stock units will vest on each of July 16, 2026, 2027, 2028 and 2029.

SEC source: 0001140361-24-043157 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 681,582

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.95 to $6.08 inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

SEC source: 0001140361-24-034270 · form4.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 634,033

F2 · shares: The exempt disposition of 3,372 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares of underlying restricted stock units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-24-034270 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 637,405

F1 · shares: The exempt disposition of 2,982 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-24-033912 · form4.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,466

Underlying: Common Stock · 7,466 shares

Expires 2034-07-19

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 19, 2025, such that 25% of the options will vest on each of July 19, 2025, 2026, 2027 and 2028.

SEC source: 0001140361-24-033912 · form4.xml · derivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,633

Underlying: Common Stock · 7,633 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-24-033912 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 640,387

F1 · shares: The acquisition of 3,817 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,817 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 19, 2025, such that 25% of the restricted stock units will vest on each of July 19, 2025, 2026, 2027 and 2028.

SEC source: 0001140361-24-033784 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 636,570

F1 · shares: The exempt disposition of 8,307 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-24-033635 · form4.xml · derivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 211,622

Underlying: Common Stock · 211,622 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-24-033635 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 644,877

F1 · shares: The acquisition of 105,811 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 105,811 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 17, 2025, such that 25% of the restricted stock units will vest on each of July 17, 2025, 2026, 2027 and 2028.

SEC source: 0001140361-24-035600 · form4.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 52,378 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 21, 2021, the reporting person received a target grant of 52,378 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 56,279 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 21, 2021, the reporting person received a target grant of 52,378 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 56,279 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 21, 2021, the reporting person received a target grant of 52,378 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 56,279 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-24-035600 · form4.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 661,582

F2 · shares: The exempt disposition of 28,730 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-24-035600 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 690,312

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 56,279 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-24-018620 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 539,066

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.64 to $6.76, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

SEC source: 0001140361-23-036120 · form4.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 529,066

F2 · shares: The exempt disposition of 3,372 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-23-036120 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 532,438

F1 · shares: The exempt disposition of 2,982 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-23-035729 · form4.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,778

Underlying: Common Stock · 190,778 shares

Expires 2033-07-19

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 19, 2024, such that 25% of the options will vest on each of July 19, 2024, 2025, 2026 and 2027.

SEC source: 0001140361-23-035729 · form4.xml · derivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 184,361

Underlying: Common Stock · 184,361 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-23-035729 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 535,420

F1 · shares: The acquisition of 92,181 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 92,181 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 19, 2024, such that 25% of the restricted stock units will vest on each of July 19, 2024, 2025, 2026 and 2027.

SEC source: 0001140361-23-036322 · form4.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 108,871 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,769 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,769 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,769 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-23-036322 · form4.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 549,259

F2 · shares: The exempt disposition of 11,379 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-036322 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 560,638

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 31,572 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044830 · form4.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 108,871 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 14, 2020, the reporting person received a target grant of 108,871 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 69,676 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 14, 2020, the reporting person received a target grant of 108,871 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 69,676 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 14, 2020, the reporting person received a target grant of 108,871 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 69,676 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-23-044830 · form4.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 564,446

F2 · shares: The exempt disposition of 34,296 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044830 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 598,742

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 69,676 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-24-033635 · form4.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 207,693

Underlying: Common Stock · 207,693 shares

Expires 2034-07-17

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 17, 2025, such that 25% of the options will vest on each of July 17, 2025, 2026, 2027 and 2028.

SEC source: 0001140361-23-035086 · form4.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 443,239

F2 · shares: The exempt disposition of 2,262 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001140361-23-035086 · form4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 445,501

F1 · shares: The exempt disposition of 4,906 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001567619-22-018410 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 450,407

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.93 to $15.02, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

SEC source: 0001567619-22-014379 · doc1.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,530

Underlying: Common Stock · 77,530 shares

Expires 2032-07-20

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 20, 2023, such that 25% of the options will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-22-014379 · doc1.xml · derivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,187

Underlying: Common Stock · 66,187 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-22-014379 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 440,407

F1 · shares: The acquisition of 33,094 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 33,094 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 20, 2023, such that 25% of the restricted stock units will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-22-013842 · doc1.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,139 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On October 16, 2019, the reporting person received a target grant of 50,139 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 25,123 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On October 16, 2019, the reporting person received a target grant of 50,139 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 25,123 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On October 16, 2019, the reporting person received a target grant of 50,139 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 25,123 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001567619-22-013842 · doc1.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 407,313

F2 · shares: The exempt disposition of 8,574 shares of Common Stock to the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-22-013842 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 415,887

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 25,123 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on October 16, 2019

SEC source: 0001567619-22-001113 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 390,764

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.58 to $23.06, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.